Research Portal

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Research output: Contribution to journal › Article › peer-review

Standard Standard

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. / Schneider, Constanze; Oellerich, Thomas; Baldauf, Hanna-Mari et al.
In: Nature Medicine, Vol. 23, No. 2, 02.2017, p. 250-255.

Research output: Contribution to journal › Article › peer-review

HarvardHarvard

Schneider, C, Oellerich, T, Baldauf, H-M, Schwarz, S-M, Thomas, D, Flick, R, Bohnenberger, H, Kaderali, L, Stegmann, L, Cremer, A, Martin, M, Lohmeyer, J, Michaelis, M, Hornung, V, Schliemann, C, Berdel, WE, Hartmann, W, Wardelmann, E, Comoglio, F, Hansmann, M-L, Yakunin, AF, Geisslinger, G, Stroebel, P, Ferreiros, N, Serve, H, Keppler, OT & Cinatl, JJ 2017, 'SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia', Nature Medicine, vol. 23, no. 2, pp. 250-255. https://doi.org/10.1038/nm.4255

APA

Schneider, C., Oellerich, T., Baldauf, H.-M., Schwarz, S.-M., Thomas, D., Flick, R., Bohnenberger, H., Kaderali, L., Stegmann, L., Cremer, A., Martin, M., Lohmeyer, J., Michaelis, M., Hornung, V., Schliemann, C., Berdel, W. E., Hartmann, W., Wardelmann, E., Comoglio, F., ... Cinatl, J. J. (2017). SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nature Medicine, 23(2), 250-255. https://doi.org/10.1038/nm.4255

CBE

Schneider C, Oellerich T, Baldauf H-M, Schwarz S-M, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, et al. 2017. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nature Medicine. 23(2):250-255. https://doi.org/10.1038/nm.4255

MLA

Schneider, Constanze et al. "SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia". Nature Medicine. 2017, 23(2). 250-255. https://doi.org/10.1038/nm.4255

VancouverVancouver

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nature Medicine. 2017 Feb;23(2):250-255. Epub 2016 Dec 19. doi: 10.1038/nm.4255

Author

Schneider, Constanze ; Oellerich, Thomas ; Baldauf, Hanna-Mari et al. / SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. In: Nature Medicine. 2017 ; Vol. 23, No. 2. pp. 250-255.

RIS

TY - JOUR

T1 - SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

AU - Schneider, Constanze

AU - Oellerich, Thomas

AU - Baldauf, Hanna-Mari

AU - Schwarz, Sarah-Marie

AU - Thomas, Dominique

AU - Flick, Robert

AU - Bohnenberger, Hanibal

AU - Kaderali, Lars

AU - Stegmann, Lena

AU - Cremer, Anjali

AU - Martin, Margarethe

AU - Lohmeyer, Julian

AU - Michaelis, Martin

AU - Hornung, Veit

AU - Schliemann, Christoph

AU - Berdel, Wolfgang E.

AU - Hartmann, Wolfgang

AU - Wardelmann, Eva

AU - Comoglio, Federico

AU - Hansmann, Martin-Leo

AU - Yakunin, Alexander F.

AU - Geisslinger, Gerd

AU - Stroebel, Philipp

AU - Ferreiros, Nerea

AU - Serve, Hubert

AU - Keppler, Oliver T.

AU - Cinatl, Jindrich, Jr.

PY - 2017/2

Y1 - 2017/2

UR - https://static-content.springer.com/esm/art%3A10.1038%2Fnm.4255/MediaObjects/41591_2017_BFnm4255_MOESM6_ESM.pdf

U2 - 10.1038/nm.4255

DO - 10.1038/nm.4255

M3 - Article

VL - 23

SP - 250

EP - 255

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -